Drug Trial Radar · NCT05067868
A Study of Replagal in Children and Adults With Fabry Disease in India
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda
- First posted
- Oct 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn more about the safety profile of Replagal. Participants will receive Replagal every 2 weeks at the clinic for about 1 year.
Conditions
- Fabry Disease
Interventions
ReplagalBiological
Participants will receive Replagal 0.2 mg/kg, intravenous infusion at Day 1 and every 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the start of study up to 53 weeks
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From the study drug administration up to Week 53
- Number of Participants With Adverse Drug Reactions (ADRs) Related to ReplagalTime frame: From the study drug administration up to Week 53
- Number of Participants With Infusion-related Reactions of ReplagalTime frame: From the study drug administration up to Week 53
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Institute of Child Health
Kolkata, India · Not yet recruiting
All India Institute of Medical Sciences (AIIMS)
New Delhi, India · Recruiting
Sir Gangaram Hospital
New Delhi, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.